The $25 price level has emerged as a focal point for TRVI investors, appearing repeatedly across Wall Street research. Cantor Fitzgerald maintains an Overweight rating with a $25 price target, while Leerink Partners raised its target to $25 from $21 in April 2026. Earlier in the year, Needham had also set a $25 target before adjusting to $23-$24. This clustering of analyst estimates around the $25 mark — coupled with its status as a round psychological number — gives the level genuine significance in market discussions.
The stock has already staged an impressive rally, climbing from approximately $6.55 in August 2025 to a 52-week high of $20.22 in July 2026 — a gain of more than 200%. Reaching $25 would represent a continued upward trajectory of roughly 38% from the latest closing price and would require sustained positive momentum from the company's clinical pipeline.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio (oral nalbuphine ER), an investigational extended-release formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. Trevi targets neurologically mediated conditions, with its primary programs addressing chronic cough in patients with IPF, non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC). The company, headquartered in New Haven, Connecticut, remains pre-revenue with a net loss of approximately $45.6 million and holds cash sufficient to fund operations into 2028 following a $173 million equity raise.
The competitive landscape shifted dramatically in Trevi's favor when GSK halted development of camlipixant in refractory chronic cough, effectively ending the P2X3 receptor antagonist class in this indication. B. Riley Securities raised its price target on TRVI from $21 to $31 specifically citing this development, noting that Haduvio now stands as "the leading differentiated candidate." This removal of a major competitor meaningfully derisks Haduvio's commercial prospects.
The addressable market for Haduvio is substantial. Leerink Partners projects peak sales of approximately $1.3 billion for IPF-related chronic cough, $1.0 billion for refractory chronic cough, and $815 million for ILD-related chronic cough — totaling over $3 billion across indications. Cantor Fitzgerald has similarly noted that unmet need across these indications can support peak sales "in the multi-billion dollar per year range."
Trevi expects to initiate multiple late-stage Phase 3 studies for Haduvio in 2026, representing major catalysts that could accelerate the stock toward the $25 target if data continues to support the therapy's efficacy and safety profile. Feedback from key opinion leaders regarding Haduvio's differentiated mechanism has been described as strong, and the company's cash position of approximately $188.3 million at the end of 2025 — bolstered by the April 2026 equity raise — provides ample runway to reach critical data readouts.
Wall Street maintains a notably bullish posture on TRVI. According to StockAnalysis, 11 analysts rate the stock a consensus "Strong Buy" with an average 12-month price target of $26.18. The range spans from Morgan Stanley's $20 to BMO Capital's Street-high $36. B. Riley Securities raised its target to $31 in July 2026, while Clear Street maintains a $29 target and Oppenheimer stands at $24. The overwhelming majority of ratings are Buy or Strong Buy, with no Hold or Sell recommendations from major firms.
This analyst enthusiasm reflects growing confidence that Trevi's Phase 2 data for Haduvio — which demonstrated an approximately 56% placebo-adjusted cough reduction in the Phase 2a RIVER trial — can translate into successful Phase 3 outcomes across multiple indications.
From a technical perspective, the $20.22 level represents the immediate overhead resistance, marking the stock's 52-week high established in mid-July 2026. A decisive breakout above this level would be the first necessary step toward any move to $25. The $25 area itself represents a psychological round-number resistance that could attract sellers. On the downside, the $16-$17 zone has served as recent support, while the stock's 50-day moving average near $13-$14 offers a deeper structural floor.
The broader structure of TRVI's price action remains in a strong long-term uptrend, with higher lows established consistently since mid-2025. This trend structure supports the bullish narrative but does not guarantee a smooth path to $25.
Despite the bullish consensus, significant risks remain. Trevi is a pre-revenue biotech company: it generates no product sales, and its entire valuation depends on clinical trial success and eventual regulatory approval. Any disappointing Phase 3 data for Haduvio — whether in efficacy, safety, or tolerability — would likely trigger a sharp repricing of the stock.
Additionally, as a mixed opioid agonist/antagonist, Haduvio carries inherent regulatory scrutiny related to its mechanism of action. While analysts note that questions about intellectual property and the perception of an opioid-based therapy have "generally been addressed," the pathway to FDA approval requires rigorous demonstration of a favorable benefit-risk profile. Competition from other therapeutic approaches to chronic cough could also emerge, and dilution risk remains a factor for a company that may need additional capital before reaching commercialization.
Traders seeking to navigate the volatility inherent in clinical-stage biotech stocks can benefit from systematic, data-driven tools. Tickeron's AI Daily Buy/Sell Signals leverage artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals as market conditions evolve. The system analyzes technical patterns, trend behavior, and AI-driven market insights to help identify emerging opportunities and flag deteriorating positions. For a stock like TRVI, where clinical catalysts and sentiment shifts can produce rapid price movements, having automated signal-based monitoring can help traders stay ahead of changing trends without constant manual chart analysis. Explore how AI-powered signals can complement your market research.
The $25 price target for Trevi Therapeutics appears realistically achievable within a 12-month horizon, provided the company executes on its clinical development plan. The strongest arguments supporting the move include the removal of GSK's camlipixant from the competitive landscape, broad analyst consensus with price targets at or above $25, a well-capitalized balance sheet that extends through key catalysts, and a multi-billion-dollar addressable market for Haduvio across multiple chronic cough indications.
However, reaching $25 is not guaranteed. The stock must first break through the $20.22 all-time high, and every Phase 3 trial carries inherent binary risk. If Haduvio's pivotal data fails to replicate the promising Phase 2 results, the bullish thesis collapses. Investors should monitor upcoming Phase 3 initiations, interim data readouts, cash burn rates, and any competitive developments in the chronic cough treatment landscape. The path to $25 exists — but it runs through clinical trial data that has yet to be produced.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with PVLA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then PVLA could also see price increases.
| Ticker / NAME | Correlation To TRVI | 1D Price Change % | ||
|---|---|---|---|---|
| TRVI | 100% | -3.84% | ||
| PVLA - TRVI | 40% Loosely correlated | -3.52% | ||
| PCVX - TRVI | 37% Loosely correlated | +0.38% | ||
| SYRE - TRVI | 37% Loosely correlated | +0.40% | ||
| NAMS - TRVI | 36% Loosely correlated | +0.07% | ||
| STOK - TRVI | 35% Loosely correlated | -1.47% | ||
More | ||||